

UTILIZATION OF *IN VITRO* CYTOCHROME P450 INHIBITION DATA FOR PROJECTING CLINICAL DRUG–DRUG INTERACTIONS

JANE R. KENNY, DERMOT F. MCGINNITY, KEN GRIME, AND ROBERT J. RILEY

AstraZeneca R&D Charnwood, Loughborough, United Kingdom

Contents

- 1 Introduction
- 2 Cytochrome P450 and Its Role in Drug–Drug Interactions
 - 2.1 Clinical Consequences of Cytochrome P450 Mediated Drug–Drug Interactions
 - 2.2 Mechanisms of Cytochrome P450 Inhibition
- 3 Assessment of Cytochrome P450 Inhibition *In Vitro*
 - 3.1 Enzyme Systems
 - 3.2 Probe Substrate Selection
 - 3.3 Analysis Methods
- 4 Generation of *In Vitro* Cytochrome P450 Inhibition Data
 - 4.1 Reversible Inhibition (IC_{50} and K_i)
 - 4.2 Mechanism-Based Inhibition (K_i , k_{inact} , and IC_{50})
- 5 *In Vitro–In Vivo* Extrapolation of Cytochrome P450 Based Drug–Drug Interactions
 - 5.1 Approach for Reversible Inhibitors
 - 5.2 Approach for Mechanism-Based Inhibitors
 - 5.3 Key Concepts
 - 5.4 FDA Guidelines
- 6 Conclusion
 - References
 - Appendix A
 - Appendix B